Aram Jehan, Francis Anna, Tanasescu Radu, Constantinescu Cris S
Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham, UK.
Department of Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Neurol Ther. 2019 Jun;8(1):45-57. doi: 10.1007/s40120-018-0120-1. Epub 2018 Dec 1.
Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system (CNS) and the most frequent cause of non-traumatic disability in adults in the Western world. Currently, several drugs have been approved for the treatment of multiple sclerosis. While the newer drugs are more effective, they have less favourable safety profiles. Thus, there is a need to identify new targets for effective and safe therapies, particularly in patients with progressive disease for whom no treatments are available. One such target is granulocyte-macrophage colony-stimulating factor (GM-CSF) or its receptor. In this article we review data on the potential role of GM-CSF and GM-CSF inhibition in MS. We discuss the expression and function of GM-CSF and its receptor in the CNS, as well as data from animal studies and clinical trials in MS.
多发性硬化症是一种中枢神经系统（CNS）的炎症性神经退行性疾病，也是西方世界成年人非创伤性残疾的最常见原因。目前，已有几种药物被批准用于治疗多发性硬化症。虽然新药更有效，但它们的安全性较差。因此，需要确定有效和安全治疗的新靶点，特别是对于没有可用治疗方法的进展性疾病患者。粒细胞-巨噬细胞集落刺激因子（GM-CSF）或其受体就是这样一个靶点。在本文中，我们综述了关于GM-CSF及其抑制在多发性硬化症中的潜在作用的数据。我们讨论了GM-CSF及其受体在中枢神经系统中的表达和功能，以及来自多发性硬化症动物研究和临床试验的数据。
